Literature DB >> 8082081

The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas.

M S Berger1, A V Deliganis, J Dobbins, G E Keles.   

Abstract

BACKGROUND: To evaluate the role of radical resection for low grade cerebral hemisphere gliomas, the authors analyzed the preoperative and postoperative radiographic tumor volumes (computed tomography hypodensity, magnetic resonance imaging-T2 signal hyperintensity) in 53 patients.
METHODS: Using a previously described method of computerized image analysis, the authors evaluated whether the percent of resection and volume of residual disease, postoperatively, influenced the incidence of recurrence, time to tumor progression, and histology of the recurrent tumor. Survival was not analyzed in this study.
RESULTS: No recurrence was detected, regardless of percent of resection and volume of residual disease, in patients with preoperative tumor volumes less than 10 cm2 (mean follow-up, 41.7 months). Patients with tumors measuring 10-30 cm3 had an incidence of recurrence and time to tumor progression of 13.6% and 58 months, respectively, compared with tumors measuring greater than 30 cm3, which had an incidence of recurrence and time to tumor progression of 41.2% and 30 months, respectively (P = 0.016). All patients (n = 13) who underwent a 100% resection had a recurrence-free follow-up period (mean, 54 months). In the remaining patients (n = 40), as the percent of resection decreased, the incidence of recurrence increased along with a shorter time to tumor progression (P = 0.03). Patients with a volume of residual disease of greater than 10 cm3 had a higher incidence of recurrence (46.2%) and a shorter time to tumor progression (30 months) compared with patients with a tumor volume of residual disease of less than 10 cm3 (incidence of recurrence, 14.8% and time to tumor progression, 50 months) (P = 0.002). Forty-six percent of patients with a tumor volume of residual disease of more than 10 cm3 had a recurrence of higher histologic grade, and this was significantly more frequent than patients with a volume of residual disease less than 10 cm3 (3.7%) (P = 0.0009). Age, radiotherapy, and histologic subtype had no influence on recurrence patterns.
CONCLUSION: For tumors greater than 10 cm3, the authors' data suggest that a greater percent of resection and a smaller volume of residual disease conveys a significant advantage, that is, terms of incidence of recurrence and the recurrent tumor phenotype, for patients with low grade cerebral hemisphere gliomas, compared with those who have a less aggressive resection or biopsy. While this may also be the case with tumors less than 10 cm3, further follow-up is necessary to determine the effect of surgery on recurrence patterns for this subset of patients.

Entities:  

Mesh:

Year:  1994        PMID: 8082081     DOI: 10.1002/1097-0142(19940915)74:6<1784::aid-cncr2820740622>3.0.co;2-d

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  113 in total

Review 1.  Intraoperative cortical mapping as a guide to the surgical resection of gliomas.

Authors:  P G Matz; C Cobbs; M S Berger
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

Review 2.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

3.  Evaluating requirements for spatial resolution of fMRI for neurosurgical planning.

Authors:  Seung-Schik Yoo; Ion-Florin Talos; Alexandra J Golby; Peter McL Black; Lawrence P Panych
Journal:  Hum Brain Mapp       Date:  2004-01       Impact factor: 5.038

4.  Functional recovery after surgical resection of low grade gliomas in eloquent brain: hypothesis of brain compensation.

Authors:  H Duffau; L Capelle; D Denvil; N Sichez; P Gatignol; M Lopes; M-C Mitchell; J-P Sichez; R Van Effenterre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

5.  Post-craniotomy neuronavigation based purely on intraoperative ultrasound imaging without preoperative neuronavigational planning.

Authors:  Inti Peredo-Harvey; Anders Lilja; Tiit Mathiesen
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

6.  Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era.

Authors:  J P Bahary; J G Villemure; S Choi; R Leblanc; A Olivier; G Bertrand; L Souhami; D Tampieri; J Hazel
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

7.  Central nervous system cancers.

Authors:  Louis Burt Nabors; Mario Ammirati; Philip J Bierman; Henry Brem; Nicholas Butowski; Marc C Chamberlain; Lisa M DeAngelis; Robert A Fenstermaker; Allan Friedman; Mark R Gilbert; Deneen Hesser; Matthias Holdhoff; Larry Junck; Ronald Lawson; Jay S Loeffler; Moshe H Maor; Paul L Moots; Tara Morrison; Maciej M Mrugala; Herbert B Newton; Jana Portnow; Jeffrey J Raizer; Lawrence Recht; Dennis C Shrieve; Allen K Sills; David Tran; Nam Tran; Frank D Vrionis; Patrick Y Wen; Nicole McMillian; Maria Ho
Journal:  J Natl Compr Canc Netw       Date:  2013-09-01       Impact factor: 11.908

8.  Assessment of verbal working memory before and after surgery for low-grade glioma.

Authors:  Pilar Teixidor; Peggy Gatignol; Marianne Leroy; Cristina Masuet-Aumatell; Laurent Capelle; Hugues Duffau
Journal:  J Neurooncol       Date:  2006-08-31       Impact factor: 4.130

9.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

10.  Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.

Authors:  Michael Wahl; Joanna J Phillips; Annette M Molinaro; Yi Lin; Arie Perry; Daphne A Haas-Kogan; Joseph F Costello; Manisha Dayal; Nicholas Butowski; Jennifer L Clarke; Michael Prados; Sarah Nelson; Mitchel S Berger; Susan M Chang
Journal:  Neuro Oncol       Date:  2017-02-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.